[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369426-105":59,"doc-detail-369426-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","multicenter-open-label-randomized-controlled-study-to-test-the-utility-of-electronic-patient-reported-outcome-monitoring-research","Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring - research","","Electronic patient-reported outcome (ePRO) monitoring for patients receiving cancer chemotherapy may enable qualified, early detection of adverse events and disease-related symptoms, supporting improved patient care. This study evaluates whether adding ePRO monitoring to routine medical care improves overall survival and quality of life. Patients with unresectable advanced cancers or metastatic/recurrent solid tumors on systemic chemotherapy are randomized to an ePRO monitoring group versus usual care, with weekly electronic symptom checks. Results are returned to medical personnel for patient care decisions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multicenter-open-label-randomized-controlled-study-to-test-the-utility-of-electronic-patient-reported-outcome-monitoring-research/369426/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multicenter-open-label-randomized-controlled-study-to-test-the-utility-of-electronic-patient-reported-outcome-monitoring-research/369426.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the purpose of adding ePRO monitoring to routine care?","Question",{"text":113,"@type":114},"To determine whether ePRO monitoring improves overall survival and health-related quality of life for cancer patients undergoing chemotherapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Who will participate in the study and how are they assigned?",{"text":118,"@type":114},"Patients with unresectable advanced cancers or metastatic/recurrent solid tumors receiving systemic chemotherapy are randomized to an ePRO monitoring group or a usual care group.",{"name":120,"@type":111,"acceptedAnswer":121},"What happens during the monitoring period and what are the primary endpoints?",{"text":122,"@type":114},"The ePRO group performs weekly symptom monitoring using an electronic device; monitoring results are returned to medical personnel for patient care. Primary endpoints are overall survival and health-related quality of life.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369426,1790478747,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors  \nNaruto Taira1 , * , Naomi Kiyota2 , Yuichiro Kikawa3 , Eiki Ichihara4 , Kyoko Kato5 , Kaoru Kubota6 , Ryosuke Tateishi7 , Akinobu Nakata8 , Keiichiro Nakamura9 , Yukiya Narita8 , Katsuyuki Hotta 10 , Hiroji Iwata11 , Akihiko Gemma6 , Kojiro Shimozuma12 , Kei Muro8 , Tetsuya Iwamoto13 , Yuki Takumoto13 , Takeru Shiroiwa13 , Takashi Fukuda13 ,  \nTakuhiro Yamaguchi14 , Yasuhiro Hagiwara15 , Hironobu Minami16  \n1 Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan  \n2 Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo, 650-0017, Japan  \n3 Department of Breast Surgery, Kansai Medical University, 2-5-1 Shin-machi, Hirakata City, Osaka, 573-1010, Japan  \n4 Center for Clinical Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan  \n5 Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001, Japan  \n6 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan  \n7 Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan  \n8 Department of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka-shi, 558-8585, Japan  \n9 Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan  \n10 Center for Innovative Clinical Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan  \n11 Department of Advanced Clinical Research and Development, Nagoya City University, 1 kawasumi, Mizuho-cho, Mizuho-ku, Nagoya City, 467-8601, Japan  \n12 Department of Biomed Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Sgiga, 525-8577, Japan  \n13 Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, 2-3-6 Minami, Wako City, Saitama, 351-0197, Japan  \n14 Division of Biostatistics, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan  \n15 Department of Biostatistics, Division of Health Sciences and Nursing, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan  \n16 Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan  \n*Corresponding author. Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan.  \nE-mail: [ntaira@med.kawasaki-m.ac.jp](ntaira@med.kawasaki-m.ac.jp)  \nAbstract  \nElectronic patient-reported outcome (ePRO) monitoring for patients undergoing cancer chemotherapy may provide qualiﬁed and early detection of adverse events or disease-related symptoms, leading to improved patient care. The aim of this study is to examine whether addition of ePRO monitoring to routine medical care contributes to improved overall survival and quality of life of cancer patients undergoing chemotherapy. Patients with unresectable advanced cancers or metastatic/recurrent solid tumors receiving systemic chemotherapy will be randomized to anePRO monitoring group and a usual care group. The ePRO group will conduct weekly symptom monitoring using an electronic device after study enrollment until the end of the study. Monitoring results will be returned to medical personnel a","cbCaisLBDOYHe9FY","https://ap.wps.com/l/cbCaisLBDOYHe9FY","pdf",1039252,"English","# Abstract\n## Study aim and rationale\n## Design and randomization\n## Monitoring workflow and clinical use\n## Endpoints and sample size","[{\"question\":\"What is the purpose of adding ePRO monitoring to routine care?\",\"answer\":\"To determine whether ePRO monitoring improves overall survival and health-related quality of life for cancer patients undergoing chemotherapy.\"},{\"question\":\"Who will participate in the study and how are they assigned?\",\"answer\":\"Patients with unresectable advanced cancers or metastatic/recurrent solid tumors receiving systemic chemotherapy are randomized to an ePRO monitoring group or a usual care group.\"},{\"question\":\"What happens during the monitoring period and what are the primary endpoints?\",\"answer\":\"The ePRO group performs weekly symptom monitoring using an electronic device; monitoring results are returned to medical personnel for patient care. Primary endpoints are overall survival and health-related quality of life.\"}]","Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring - research | PDF",1790182604,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cdd3b9d0c1e6a221cab44aab69384dbb.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/721817f3d307b06dca12ebc584a9b63a.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30bbaafaa098b58ffef2b85232854c59.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1adfdaf2e1d350b8d35eab4b1f397dba.webp",980,1287]